Nonprofit drugs as the salvation of the world's healthcare systems: The case of Antabuse (disulfiram)

Drug Discovery Today

Volumn 17, Issue 9-10, 2012, Pages 409-412

  Cvek, Boris ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER COMPLEX; COPPER DIETHYLDITHIOCARBAMATE; DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; GENERIC DRUG; GLUCONATE COPPER; GLUCONATE ZINC; PAROMOMYCIN; PLACEBO; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOLISM; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; COMMERCIAL PHENOMENA; DISEASE FREE SURVIVAL; DRUG CONTROL; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG REPURPOSING; DRUG SAFETY; EVENING DOSAGE; FUNDING; GASTROINTESTINAL TOXICITY; GOVERNMENT; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LICENSING; LIVER CANCER; LIVER METASTASIS; MORNING DOSAGE; MUCOSA INFLAMMATION; NON PROFIT ORGANIZATION; NONHUMAN; OVERALL SURVIVAL; PATENT; REVIEW; SOCIAL WELFARE; SURVIVAL RATE; VISCERAL LEISHMANIASIS;

EID: 84860680012     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.12.010     Document Type: Short Survey

References (44)

1. A. Mullard Could pharma open its drug freezers? Nat. Rev. Drug Discov. 10 2011 399 400
2. F.S. Collins Mining for the therapeutic gold Nat. Rev. Drug Discov. 10 2011 397
3. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
4. M.J. Keiser Predicting new molecular targets for known drugs Nature 462 2009 175 181
5. J.A. DiMasi The price of innovation: new estimates of drug development costs J. Health Econ. 22 2003 185 251
6. C.R. Chong, and D.J. Sullivan New uses for old drugs Nature 448 2007 645 646
7. O. Minovetski, and D. Nicol Are patents for methods of medical treatment contrary to the ordre public and morality or 'generally inconvenient'? J. Med. Ethics 30 2004 470 477
8. T.T. Ashburn, and K.B. Thor Drug repositioning: identifying and developing new uses for existing drugs Nat. Rev. Drug Discov. 3 2004 673 683
9. B.N. Roin Unpatentable drugs and the standards of patentability Texas Law Rev. 87 2009 503 570
10. S.N. Deftereos Drug repurposing and adverse event prediction using high-throughput literature analysis Wiley Interdiscip. Rev. Syst. Biol. Med. 3 2011 323 334
11. B.M. Padhy, and Y.K. Gupta Drug repositioning: re-investigating existing drugs for new therapeutic indications J. Postgrad. Med. 57 2011 153 160
12. E.R. Gold Are patents impeding medical care and innovation? PLoS Med. 7 2010 E1000208
13. T. Fojo, and C. Grady How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question J. Natl Cancer Inst. 101 2009 1044 1048
14. V.G. Hale Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world Health Aff. (Millwood) 24 2005 1057 1063
15. R.N. Davidson Paromomycin Trans. R. Soc. Trop. Med. Hyp. 103 2009 653 660
16. R.K. Singh Visceral leishmaniasis (kala-azar): challenges ahead Indian J. Med. Res. 123 2006 331 344
17. R. Sarnoff The economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India Trop. Med. Int. Health 15 2010 42 49
18. S. Sundar Injectable paromomycin for visceral leishmaniasis in India N. Engl. J. Med. 356 2007 2571 2581
19. B. Cvek Antabuse (disulfiram) as a pilot case of nonprofit drug Int. J. Cancer 127 2010 2486
20. B. Cvek Antabuse repurposing: we need more knowledge and wide international support Int. J. Cancer 129 2011 1286 1287 (Epub ahead of print)
21. E. Marshall Cancer research and the $90 billion metaphor Science 331 2011 1540 1541
22. P. Porter 'Westernizing' women's risks? Breast cancer in low-income countries N. Engl. J. Med. 358 2008 213 216
23. B.O. Anderson Optimization of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus 2010 Lancet Oncol. 12 2011 387 398
24. K.R. Loughlin, and J.A. Generali The Guide to Off-Label Prescription Drugs: New Uses for FDA-Approved Prescription Drugs 2006 Simon & Schuster
25. P. Wicks Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm Nat. Biotechnol. 29 2011 411 414
26. M.S. Boguski Repurposing with a difference Science 324 2009 1394 1395
27. B. Cvek, and Z. Dvorak The value of proteasome inhibition in cancer. Can the old drug, disulfiram, has a bright new future as a novel proteasome inhibitor? Drug Discov. Today 13 2008 716 722
28. B. Cvek Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome Curr. Cancer Drug Targets 11 2011 332 337
29. J.J. Suh The status of disulfiram: a half of a century later J. Clin. Psychopharmacol. 26 2006 290 302
30. C.C. Irving Inhibition of N-n-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancer in rats by administration of disulfiram in the diet Cancer Res. 39 1979 3040 3043
31. C.C. Irving The effect of disulfiram on the carcinogenecity of N-butyl-N-(3-carboxypropyl)nitrosamine in the rat Carcinogenesis 4 1983 617 620
32. C.C. Irving, and D.S. Daniel Influence of disulfiram on the metabolism of the urinary bladder carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine Carcinogenesis 8 1987 1309 1315
33. D. Chen Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity Cancer Res. 66 2006 10425 10433
34. B. Cvek Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells J. Med. Chem. 51 2008 6256 6258
35. E.F. Lewison Spontaneous regression of breast cancer Prog. Clin. Biol. Res. 12 1977 47 53
36. P. Dufour Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study Biotherapy 6 1993 9 12
37. D.I. Eneanya The actions and metabolic fate of disulfiram Annu. Rev. Pharmacol. Toxicol. 21 1981 575 596
38. R.C. Vallari, and R. Pietruszko Human aldehyde dehydrogenase: mechanism of inhibition of disulfiram Science 216 1982 637 639
39. J.M. Lang Randomized, double-blind, placebo-controlled trial of ditiocarb sodium (Imuthiol) in human immunodeficiency virus infection Lancet 332 1988 702 706
40. E.C. Reisinger Inhibition of HIV progression by ditiocarb. German DTC study group Lancet 335 1990 679 682
41. E.M. Hersh Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study JAMA 265 1991 1538 1544
42. B. Cvek Failure of ditiocarb (diethyldithiocarbamate) therapy: was diet the reason? Curr. HIV Res. 7 2009 254
43. Y. Suzuki The origin of an EPR signal observed in dithiocarbamate-loaded tissues. Copper(II)-dithiocarbamate complexes account for the narrow hyperfine lines Biochim. Biophys. Acta 1335 1997 242 245
44. S.S. Brar Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease Mol. Cancer Ther. 3 2004 1049 1060